Share on StockTwits

Research analysts at Stifel Nicolaus reduced their price objective on shares of Evotec AG (NASDAQ:EVTC) from $28.00 to $27.00 in a report released on Thursday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target points to a potential upside of 19.89% from the company’s current price.

Separately, analysts at Goldman Sachs initiated coverage on shares of Evotec AG in a research note on Tuesday, July 8th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $26.50.

Shares of Evotec AG (NASDAQ:EVTC) traded down 1.83% on Thursday, hitting $22.04. The stock had a trading volume of 89,047 shares. Evotec AG has a one year low of $20.64 and a one year high of $26.33. The stock has a 50-day moving average of $23.45 and a 200-day moving average of $23.95. The company’s market cap is $1.727 billion.

Evotec AG (NASDAQ:EVTC) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.41 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.40 by $0.01. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $94.40 million. During the same quarter last year, the company posted $0.35 earnings per share. Evotec AG’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Evotec AG will post $1.68 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Monday, August 18th will be given a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.78%.

Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.